<DOC>
	<DOCNO>NCT02027935</DOCNO>
	<brief_summary>The goal clinical research study learn safety give CD8+T cell ipilimumab , cyclophosphamide , IL-2 ( aldesleukin ) . Researchers also want learn combination help control metastatic melanoma . This study divide 2 part : leukapheresis treatment . In leukapheresis part , blood cell collect make modified CD8+T cell give back treatment part . CD8+T cell type white blood cell . Researchers grow T cell laboratory , design find melanoma cancer cell may kill . Ipilimumab aldesleukin design increase immune system 's ability fight cancer . Cyclophosphamide use low dose weaken body 's natural defense T-cell transplant , transplant T-cells chance grow multiply .</brief_summary>
	<brief_title>Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells Anti-CTLA4</brief_title>
	<detailed_description>Study Drug Administration : If agree take part study , receive cyclophosphamide vein 30-60 minute Day -2 ( 2 day receive CD8+ T cell ) . If doctor think need , give standard drug help decrease risk side effect . You may ask study staff information drug give risk . On Day 0 , receive CD8+ T cell vein 30-60 minute . You stay hospital overnight dose . Starting within 6 hour CD8+T cell infusion 2 time day 14 day , give aldesleukin injection skin around abdomen . You teach give injection . On Days 1 , 22 , 43 , 64 , receive ipilimumab vein 90 minute . Study Visits : On Day -2 : - You physical exam . - Blood ( 1 tablespoon ) drawn routine test . This routine blood draw include pregnancy test become pregnant . To continue participation study , pregnant . On Days 0 , 7 , 14 , 22 , 28 , 35 , 43 , 49 , 56 , 64 , 70 , 77 , 84 , 112 , 140 : - You physical exam . - Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . - Between Day 35 42 Day 77 84 , CT scan check status disease . On Day 3 , blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . If doctor think need confirm status disease , blood ( 1½ tablespoon ) draw every 3-6 month 3 year . The study test may repeat may additional test perform anytime doctor think need . Some study test may do local clinic return MD Anderson . The study staff discus . Length Treatment : The treatment portion study last Day 64 . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up . End-of-Study Visit : At Day 168 : - You physical exam . - Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . Follow-Up : Every 3 month Day 84 , unless disease get bad start another cancer therapy , CT scan x-ray check status disease . Every 3 month 5 year , study staff call ask doctor . If call , call last 10-15 minute . If doctor think need , return clinic every 4-6 week often doctor think need . Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . This investigational study . CD8+T cell FDA approve commercially available . They currently use research purpose . Cyclophosphamide , ipilimumab , aldesleukin FDA approve commercially available way use study . Up 30 participant enrol multicenter study . Up 20 take part MD Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histopathologic documentation melanoma concurrent diagnosis metastatic disease . 2 . Male female subject &gt; /= 18 year age . 3 . Expression HLAA2 . 4 . ECOG/ Zubrod performance status '01 ' screen visit . 5 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study manner risk pregnancy minimize . Suggested precaution use minimize risk pregnancy least 1 month start therapy , woman study 3 month T cell infusion , least 8 week study drug stop . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal . 6 . Men must willing able use acceptable method birth control , least 3 month completion study , sexual partner WOCBP . 7 . Willing able give inform consent . 8 . Adequate venous access consider PICC central line . 9 . Evaluation BRAFV600 mutation status . 10 . Measurable tumor ( RECIST criterion ) . 11 . MART 1 SLC45A2 ( + ) stain result . ( If patient stain test past , test run patient consent obtain , enrollment ) . 1 . Any malignancy patient diseasefree less 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix . 2 . Pregnant woman , nurse mother , men woman reproductive ability unwilling use effective contraception . Women childbearing potential positive pregnancy test within 3 day prior entry . 3 . Active untreated central nervous system ( CNS ) metastasis ( include metastasis identify screen MRI contrast CT ) . • No sign symptom CNS mets within last 30 day ( enrollment evaluation ) . • No single lesion large 1cm • No 5 lesion 4 . Autoimmune disease : Patients history Inflammatory Bowel Disease exclude study , patient history autoimmune disease ( e.g . Systemic Lupus Erythematosus , vasculitis , infiltrate lung disease ) whose possible progression treatment would consider Investigator unacceptable . 5 . Any underlying medical psychiatric condition , opinion Investigator , make administration study drug hazardous obscure interpretation adverse event , condition associate frequent diarrhea . 6 . Positive screening test HIV , Hep B , Hep C ( reference blood draw leukapheresis screen ) . If positive result indicative true active chronic infection , patient treat . 7 . CBC Chemistry profile prior cyclophosphamide T cell infusion : •WBC &lt; /= 1000/uL •Hct &lt; /= 24 % Hemoglobin &lt; /=8 g/dL •ANC &lt; /= 500 •Platelets &lt; /= 50,000 •Creatinine &gt; /= 3.0 x ULN •AST/ALT &gt; /= 2.5 x ULN , •Bilirubin &gt; /= 3 x ULN 8 . Steroids permit 3 day prior T cell infusion concurrently therapy . 9 . Any nononcology vaccine therapy use prevention infectious disease within 1 month ipilimumab dose . 10 . Patients may treatment cancer aside include protocol . Patients may undergo another form treatment concurrently study . 11 . Pregnant woman , nurse mother , men woman reproductive ability unwilling use effective contraception . Women childbearing potential positive pregnancy test within 3 day prior entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>CD8+ T cell</keyword>
	<keyword>White blood cell</keyword>
	<keyword>Leukapheresis</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>IL-2</keyword>
	<keyword>Proleukin</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Yervoy</keyword>
	<keyword>BMS-734016</keyword>
	<keyword>MDX010</keyword>
</DOC>